Our focus is on Southern California, the hub for some of the world’s leading research institutions and home to our founding physicians.
Inspired by the most promising science, we fund leading local researchers, making us a launchpad for additional funding and discoveries here and on the global stage.
Our focus is funding basic scientific research to uncover the mechanisms by which cancer develops and spreads, creating a path to effectively treating and preventing the disease.
These grants include:
- One-Year Career Development Grants
- Five-Year $500,000 Senior Investigator Grants
- $1M Multidisciplinary Discovery Funds
Novel Drug Targets for High Grade Serous Ovarian Cancer identified through Induced Pluripotent Stem Cell Modeling of Disease
$500,000 Tower Senior Investigator Grant
Faults in high risk genes cause high grade serous ovarian cancer (HGSOC). This cancer is often lethal in patients. Novel drugs are needed to improve treatment and patient outcomes. We plan to use cells from individuals carrying high risk genes to develop precision models of their disease and then cutting edge methods in genomics and functional screens to identify novel therapeutic targets that can be tested for their potential to treat patients with HGSOC. Ultimately we expected these studies will improve survival rates in patients that get HGSOC because they carry faulty genes.Simon Gayther, PhDCedars-Sinai Medical Center
Cold Atmospheric Plasma for the Treatment of NF1-related Peripheral Nerve Sheath Tumors
$100,000 Angie and Michael David Career Development Grant
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas for which the only effective therapy is surgery and NF1 patients have a greater risk of developing these tumors from plexiform neurofibromas. These tumors are collectively known as Peripheral Nerve Sheath Tumors (PNSTs). One area of active research in plasma medicine is the use of cold atmospheric plasma (CAP) in treating tumors. In this proposal, we want to investigate the role of CAP in treating NF1-related PNSTs.Brian Na, MDUniversity of California, Los Angeles
Epigenetic control of stem cell plasticity in colorectal cancer development and recurrence
$100,000 Tower Career Development Grant
Colorectal cancer (CRC) is the second-most lethal cancer in the United States causing 50,000 deaths annually. Cancer is caused by alterations in genetic material called mutations, however correcting such changes remains unfeasible. Additionally, non-genetic structural and chemical changes are essential for cancer to gain aggressive growth potential and evading therapy. Although such non-genetic changes are essentially reversible using therapeutic drugs, details of how and when they occur during CRC progression remains unknown. Using cutting-edge human CRC and mouse model systems, we will characterize the non-genetic changes during CRC growth and identify novel factors that can be targeted for innovative therapies.Unmesh Jadhav, PhDUniversity of Southern California
Single Cell Spatial Analysis of DLBCL to Develop Biomarkers and Optimize CAR T Therapy
$100,000 Tower Career Development Grant
Recently we have discovered ways to reinvigorate the immune system to fight cancer. However, in immune cancers such as lymphoma, the line between cancer and the immune system is blurred. This presents an opportunity to learn how immune cells attack cancer under complex conditions, which is called the tumor microenvironment. I propose to use a spatial protein analysis technology to identify clues, not just in cancer cells but also in the embedded immune cells, that predict cancer outcomes. Further, I will study how genetically engineered anti-tumor immune cells operate in the tumor microenvironment to improve their efficacy.Alexander Xu, PhDCedars-Sinai Medical Center
2021 Senior Investigator
Simon Gayther, PhD
Research Title: Novel Drug Targets for High-Grade
Serous Ovarian Cancer identified through
Induced Pluripotent Stem Cell Modeling of Disease
Inspired by the most promising science, we’re creating outsized impact.
*Data from the inception of TCRF’s Career Development Grants in 2006 to 2021
Scientific Advisory Board
Impact begins here,
and it starts with you.
Together we can build a better future, free from the burden of cancer.
All of our research is made possible through the generous support of people like you.